

PCT
F4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Esteban Celis
Serial No. : 10/517,800 ✓
Filed : December 13, 2004
Title : EPSTEIN-BARR VIRUS-SPECIFIC IMMUNIZATION

Art Unit : Unknown
Examiner : Unknown

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Date: 11/3/05

Respectfully submitted,

Stuart Macphail, Ph.D., J.D.
Reg. No. 44,217

Fish & Richardson P.C.
Citigroup Center - 52nd Floor
153 East 53rd Street
New York, New York 10022-4611
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

30253875.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


November 3, 2005

Date of Deposit

Signature

Maryann White

Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-407US1	Application No. 10/517,800
		Applicant Esteban Celis	
		Filing Date December 13, 2004	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,662,907	09/02/1997	Kubo et al.			
	AB	5,869,453	02/09/1999	Moss et al.			
	AC	6,162,440	12/19/2000	Hayward et al.			
	AD						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE	WO95/24925	09/21/1995	WIPO				
	AF							
	AG							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AH	Babcock et al., "EBV Persistence in Memory B Cells In Vivo", Immunity, 1998, 9:395-404
	AI	Cristiano et al., "Molecular conjugates: a targeted gene delivery vector for molecular medicine", J. Mol. Med., 1995, 73:479-486
	AJ	Di Tommaso et al., "Induction of Antigen-Specific Antibodies in Vaginal Secretions by Using a Nontoxic Mutant of Heat-Labile Enterotoxin as a Mucosal Adjuvant", Infect. Immunity, 1996, 64:974-979
	AK	Finberg, "Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas", Current Opinion Oncology, 2001, 13:349-353
	AL	Hopwood et al., "The role of EBV in post-transplant malignancies: a review", J. Clin. Pathol., 2000, 53:248-254
	AM	Hsieh et al., "The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease", Transpl. Infect. Dis., 1999, 1:204-212
	AN	Khanna et al., "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease", Proc. Natl. Acad. Sci. USA, 1999, 96(18):10391-10396
	AO	Khanna et al., "Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing", Int. Immunol., 1997, 9(10):1537-1543
	AP	Khanna et al., "Class I Processing-Defective Burkitt's Lymphoma Cells Are Recognized Efficiently by CD4 ⁺ EBV-Specific CTLs", J. Immunol., 1997, 158(8):3619-3625
	AQ	Kieff, "Epstein-Barr Virus and Its Replication" Fields Virology, 1996, Fields, Knipe, and Howley, eds. Lipincott-Raven Publishers, New York, pp.2343-2396

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-407US1	Application No. 10/517,800
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Esteban Celis	
		Filing Date December 13, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AR	Kobayashi et al., "Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles", Cancer Res., 2001, 61:4773-4778
	AS	Kobayashi et al., "Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/ <i>neu</i> Tumor Antigen", Cancer Res., 2000, 60:5228-5236
	AT	Lu et al., "Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes", Cancer Res., 2000, 60:5223-5227
	AU	Marsh, "Nomenclature for Factors of the HLA System, Update March 2002", Human Immunol., 2002, 63:515-516
	AV	Nalesnik, "Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)", Springer Semin. Immunopathol., 1998, 20:325-342
	AW	Nikiforow et al., "CD4 ⁺ T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation", J. Virol., 2001, 75(8):3740-3752
	AX	Paya et al., "Epstein-Barr Virus-Induced Posttransplant Lymphoproliferative Disorders", Transplantation, 1999, 68(10):1517-1525
	AY	Penix et al., "Two Essential Regulatory Elements in the Human Interferon γ Promoter Confer Activation Specific Expression in T Cells", J. Experim. Med., 1993, 178:1483-1496
	AZ	Rickinson et al., "Human Cytotoxic T Lymphocyte Responses to Epstein-Barr Virus Infection", Ann. Rev. Immunol., 1997, 15:405-31
	AAA	Rowe, "Epstein-Barr Virus Immortalization and Latency", Front. Biosci., 1999, 4:D346-371
	ABB	Sigal et al., "Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction", Annu. Rev. Immunol., 1992, 10:510-560
	ACC	Southwood et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires", J. Immunol., 1998, 160:3363-3373
	ADD	Thomson et al., "Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4 ⁺ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design", J. Virol., 1998, 72(3):2246-2252
	AEE	Thompson et al., " <i>cis</i> -Acting Sequences Required for Inducible Interleukin-2 Enhancer Function Bind a Novel Ets-Related Protein, Elf-1", Mol. And Cell. Biol., 1992, 12(3):1043-1053
	AFF	Todd et al., "Transcription of the Interleukin 4 Gene Is Regulated by Multiple Promoter Elements", J. Exp. Med., 1993, 177:1663-1674
	AGG	Yamamoto et al., "Mutants in the ADP-ribosyltransferase Cleft of Cholera Toxin Lack Diarrheagenicity by Retain Adjuvanticity", J. Exp. Med., 1997, 185(7):1203-1210

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	